Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials

Afatinib is an effective therapy for metastatic non-small cell lung cancer (NSCLC) but it is associated with a relatively high incidence of severe diarrhea. The association between pre-treatment candidate predictors (age, sex, race, performance status, renal function, hemoglobin, and measures of bod...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Ashley M., Nguyen, Anh-Minh, Karapetis, Christos S., Rowland, Andrew, Sorich, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210178/
https://www.ncbi.nlm.nih.gov/pubmed/30326638
http://dx.doi.org/10.3390/cancers10100384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210178/
https://www.ncbi.nlm.nih.gov/pubmed/30326638
http://dx.doi.org/10.3390/cancers10100384

Ejemplares similares